Inhibition of mutated, activated BRAF in metastatic melanoma, N. Engl. J. Med, vol.363, pp.809-819, 2010. ,
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib, N. Engl. J. Med, vol.366, pp.707-714, 2012. ,
Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance, Nature, vol.494, pp.251-255, 2013. ,
Metastatic melanoma: insights into the evolution of the treatments and future challenges, Med. Res. Rev, vol.37, pp.98-148, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01589727
CTLA-4 and PD1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients, Clin. Cancer Res, vol.19, pp.5300-5309, 2013. ,
Cell cycle regulators in the control of metabolism, Cell Cycle, vol.8, pp.4029-4031, 2009. ,
URL : https://hal.archives-ouvertes.fr/inserm-00442943
The dark side of E2F1: in transit beyond apoptosis, Cancer Res, vol.72, pp.571-575, 2012. ,
Transcription addiction: can we garner the Yin and Yang functions of E2F1 for cancer therapy?, Cell Death Dis, vol.5, p.1360, 2014. ,
A small-molecule E2F inhibitor blocks growth in a melanoma culture model, Cancer Res, vol.68, pp.6292-6299, 2008. ,
E2F1-dependent oncogenic addiction of melanoma cells to MDM2, Oncogene, vol.31, pp.828-841, 2012. ,
E2F1 in melanoma progression and metastasis, J. Natl. Cancer Inst, vol.102, pp.127-133, 2010. ,
Novel genes associated with malignant melanoma but not benign melanocytic lesions, Clin. Cancer Res, vol.11, pp.7234-7242, 2005. ,
Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival, Proc. Natl. Acad. Sci. USA, vol.106, pp.20429-20434, 2009. ,
Microphthalmia-associated transcription factor controls the DNA damage response and a lineage-specific senescence program in melanomas, Cancer Res, vol.70, pp.3813-3822, 2010. ,
Mitochondrial oxidative stress is the Achille's heel of melanoma cells resistant to Braf mutant inhibitor, Oncotarget, vol.4, pp.1986-1998, 2013. ,
Increased gene copy number of the transcription factor E2F1 in malignant melanoma, Cancer Biol. Ther, vol.5, pp.407-412, 2006. ,
Requirement forp27(KIP1) in retinoblastoma protein-mediated senescence, Mol. Cell. Biol, vol.21, pp.3616-3631, 2001. ,
An Rb-Skp2-p27 pathway mediates acute cell cycle inhibition by Rb and is retained in a partial-penetrance Rb mutant, Mol. Cell, vol.16, pp.47-58, 2004. ,
Terminal osteoblast differentiation, mediated by runx2 and p27KIP1, is disrupted in osteosarcoma, J. Cell Biol, vol.167, pp.925-934, 2004. ,
p53-Independent regulation of p21Waf1/Cip1 expression and senescence by PRMT6, Nucleic Acids Res, vol.40, pp.9534-9542, 2012. ,
Translation reprogramming is an evolutionarily conserved driver of phenotypic plasticity and therapeutic resistance in melanoma, Genes Dev, vol.31, pp.18-33, 2017. ,
Feedback between p21 and reactive oxygen production is necessary for cell senescence, Mol. Syst. Biol, vol.6, p.347, 2010. ,
Vemurafenib synergizes with nutlin-3 to deplete survivin and suppresses melanoma viability and tumor growth, Clin. Cancer Res, vol.19, pp.4383-4391, 2013. ,
Combined Inhibition of MEK and Plk1 has synergistic antitumor activity in NRAS mutant melanoma, J. Invest. Dermatol, vol.135, pp.2475-2483, 2015. ,
, Lancet, vol.383, pp.816-827, 2014.
In vitro and in vivo anti-melanoma effects of ciglitazone, J. Invest. Dermatol, vol.129, pp.1208-1218, 2009. ,
URL : https://hal.archives-ouvertes.fr/hal-02194090
Increased CD271 expression by the NF-kB pathway promotes melanoma cell survival and drives acquired resistance to BRAF inhibitor vemurafenib, Cell Discov, vol.1, p.15030, 2015. ,
Ciglitazone negatively regulates CXCL1 signaling through MITF to suppress melanoma growth, Cell Death Differ, vol.18, pp.109-121, 2011. ,
URL : https://hal.archives-ouvertes.fr/hal-00551041
Compounds triggering ER stress exert anti-melanoma effects and overcome BRAF inhibitor resistance, Cancer Cell, vol.29, pp.805-819, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01357448
Inhibition of melanogenesis by the antidiabetic metformin, J. Invest. Dermatol, vol.134, pp.2589-2597, 2014. ,
Metformin blocks melanoma invasion and metastasis development in a p53-dependent manner, Mol. Cancer Ther, vol.12, pp.1605-1615, 2013. ,
Mechanism of melanoma cells selective apoptosis induced by a photoactive NADPH Analogue, Oncotarget, vol.7, pp.82804-82819, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01604167